Everyone, everywhere, should have access to COVID-19 vaccines.
Major progress has been made with the COVID-19 vaccination response, and it is critical to continue the progress, particularly for those most at risk of disease.
WHO recommends a simplified single-dose regime for primary immunization for most COVID-19 vaccines which would improve acceptance and uptake and provide adequate protection at a time when most people have had at least one prior infection.
Available data suggest the monovalent Omicron XBB vaccines provide modestly enhanced protection compared to bivalent variant-containing vaccines and monovalent index virus vaccines.
When monovalent XBB vaccines are not available, any available WHO emergency-use listed or prequalified vaccine, bivalent variant-containing or monovalent index virus vaccines, may be used since they continue to provide benefits against severe disease in high-risk groups.
- Read WHO’s Global COVID-19 Vaccination Strategy outlining the steps to achieve effective and equitable distribution of vaccines.
- See WHO’s landscape of COVID-19 vaccine candidates for the latest information on vaccines in clinical and pre-clinical development.
- WHO’s COVID-19 dashboard also features the number of vaccine doses administered globally, with more detail provided on the dedicated COVID-19 vaccination dashboard.
- At a regional level, there is an AFRO COVID-19 vaccines dashboard and a PAHO COVID-19 vaccines deliveries dashboard.
- You can follow the status of COVID-19 Vaccines within WHO EUL/PQ evaluation process here.
Public Advice
COVID-19 vaccines explained
COVID-19 questions answered
Advice on getting vaccinated
Q&As
Coronavirus disease (COVID-19): Vaccines and vaccine safety Coronavirus disease (COVID-19): Vaccines and vaccine safety
Coronavirus disease (COVID-19): Vaccines safety Coronavirus disease (COVID-19): Vaccines safety
Coronavirus disease (COVID-19): Vaccine access and allocation Coronavirus disease (COVID-19): Vaccine access and allocation
Coronavirus disease (COVID-19): Vaccine research and development Coronavirus disease (COVID-19): Vaccine research and development
Coronavirus disease (COVID-19): Use of Emergency Use Listing procedure for vaccines against COVID-19 Coronavirus disease (COVID-19): Use of Emergency Use Listing procedure for vaccines against COVID-19
Vaccines and immunization: What is vaccination? Vaccines and immunization: What is vaccination?
Vaccines and immunization: Vaccine safety Vaccines and immunization: Vaccine safety
Delivering safe and effective vaccines
Regulation and policy
Other resources
Criteria for COVID-19 vaccine prioritization
The proposed attributes and criteria provide considerations for the evaluation and prioritization of COVID-19 candidate vaccines to be considered for further development by WHO. The target audience includes vaccine scientists, product developers, manufacturers, regulators and funding agencies.
Vaccine target product profile
WHO has published the target product profiles for COVID-19 vaccines, which describes the preferred and minimally acceptable profiles for human vaccines for long term protection of persons at high ongoing risk of COVID-19, and for reactive use in outbreak settings with rapid onset of immunity. We have also published the criteria for prioritization of vaccines for clinical trials.